Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Breast 1

Conditions

Breast Neoplasms 24Hereditary Sensory and Autonomic Neuropathies 6Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Ovarian Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Head and Neck Neoplasms 2Advanced Breast Cancer 2Triple Negative Breast Neoplasms 1Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein 1Pre-menopausal Breast Cancer 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Kidney Neoplasms 1Hyperglycemia 1HER2-positive Metastatic Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Advanced or Metastatic ER+ Breast Cancer 1Advanced and Selected Solid Tumors 1Advanced Solid Tumors With an Alteration of the PIK3CA Gene 1Advanced Solid Tumor 1Advanced HER2+Breast Cancer 1

Interventions

pembrolizumab 72Cisplatin 57Cetuximab 38Fluorouracil 25Nivolumab 21Radiotherapy 20Carboplatin 19Paclitaxel 14Docetaxel 11Cyclophosphamide 9Gefitinib 8fludarabine 7durvalumab 7zalutumumab 6atezolizumab 6Drug Therapy 6Bleomycin 6epacadostat 5cemiplimab 5Radiotherapy, Intensity-Modulated 5Pemetrexed 5Ipilimumab 5Gemcitabine 5Afatinib 5spartalizumab 4Standard of Care 4Radiation 4Injections 4Immune Checkpoint Inhibitors 4Fibroblast Growth Factor 7 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Head and Neck Neoplasms × Alpelisib × Clear all
NCT04997902 2026-06-05

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Kura Oncology, Inc.

Phase 1/2 Completed
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Recurrence

NCT02051751 2020-12-08

A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer

Novartis

Phase 1 Completed
19 enrolled
BreastHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡